Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

The medical world relies on horseshoe crab blood in the production of vaccines and equipment. A synthetic is available, but ...

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.